SOURCE: RefleXion Medical

RefleXion Medical

October 19, 2015 15:29 ET

RefleXion Medical Achieves Major Milestones in Development of Biologically-Guided Radiotherapy

Company Completes Proof-of-Concept Prototype System and Collaborates With the University of Texas MD Anderson Cancer Center on Treatment Planning Study

HAYWARD, CA--(Marketwired - October 19, 2015) - RefleXion Medical, a privately held medical equipment company, announced today that it has completed a proof-of-concept prototype system and will be sharing key results at the 57th Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Antonio, TX.

RefleXion’s unique combination of PET imaging and external beam radiotherapy could improve tumor targeting, reduce toxicity and enable efficient treatment of multiple moving tumors in the body. Biologically-guided radiotherapy could also lead to transformative new clinical applications by leveraging novel PET radiotracers that probe different aspects of tumor biology.

“With the completion of a proof-of-concept system in under one year, we have mitigated all of the key technology risks in developing a combined PET-radiotherapy system,” said RefleXion President, Dr. Samuel Mazin. “We look forward to working with select research partners in bringing this technology into the clinic.”

RefleXion will also present results at ASTRO from a collaboration with The University of Texas MD Anderson Cancer Center. Dr. Jim Welsh, a physician-scientist at MD Anderson and RefleXion Scientific Advisor, mentioned, “The treatment planning studies completed by MD Anderson suggest that biologically-guided radiotherapy has significant potential in reducing toxicity to surrounding healthy tissue. This is one of several important new clinical applications that could be enabled by RefleXion’s technology.”

Monday October 19, 5:30PM – 6:45PM, Poster Viewing Reception

Dosimetric Comparison of Emission-Guided Radiation Therapy, Volumetric Modulated Arc Therapy, and Intensity-Modulated Proton Therapy for Thoracic Tumors

Steven N. Seyedin, Osama R. Mawlawi, Lehendrick M. Turner, Samuel R. Mazin, Yevgen Voronenko, Cody Adam Wages, Peter D. Olcott, Joe Y Chang, Daniel R. Gomez, Ritsuko U. Komaki, Peter A. Balter, and James W. Welsh

About MD Anderson:

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 45 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No.1 for cancer care in U.S. News & World Report’s “Best Hospital’s” survey. It has ranked as one of the nation’s top two hospitals since the survey began in 1990, and has ranked first for 11 of the past 14 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

About RefleXion Medical:

RefleXion Medical is a privately held medical device company developing the first biologically-guided radiation therapy system for cancer treatment. By leveraging Positron Emission Tomography (PET) in a novel way, RefleXion's patented technology will allow tumors to continuously signal their location during treatment and potentially revolutionize the practice of radiation oncology. Funding for portions of RefleXion's research efforts comes from the National Cancer Institute at the National Institutes of Health, part of the U.S. Department of Health and Human Services (R43CA153466 and R44CA153466). RefleXion is backed by premier venture capital firms Sofinnova Partners, Pfizer Venture Investments and Venrock. For more information, visit www.reflexionmedical.com and follow @reflexionmed on Twitter.

The RefleXion system is not currently available for sale or clinical use.

Contact Information